Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026 ended September 30, 2025, representing an increase of $17.4 million, or approximately 92%, compared to the same period in the prior fiscal year. Income from operations was $8.2 million, an increase of $4.7 million, or approximately 136%, compared to the comparable period of the prior year. The increase in revenue and income from operations was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the prior year's comparable period, as well as overall growth in Elite label product lines. The company will host a conference call to discuss these results and recent business developments.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elite Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 274523) on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.